Abstract
Background: Pathogens colonizing the lower respiratory tract (LRT) form robust persistent biofilms, that contribute to chronic infections. Recent research shows the growing importance of amino acids’ impact on biofilm eradication. Amino acids, by enhancing physicochemical properties such as drug solubility and disrupting extracellular DNA (eDNA) are promising adjuvants that can help overcome biofilm associated AMR.1
Objectives: In this study, D-leucine has been evaluated for its anti-biofilm activity against monomicrobial and polymicrobial biofilms of Pseudomonas aeruginosa. The synergistic interactions between D-leucine and amikacin against monomicrobial microbes were comprehended.
Methods: The potential of this amino acid was assessed using MIC assay, chequerboard assay, crystal violet staining and confocal fluorescence live/dead assay imaging techniques.
Results: D-leucine demonstrated significant biofilm inhibition by up to 63.3% reduction in density as compared to the untreated control biofilm at a concentration of 40 mM. Confocal fluorescence laser scanning microscopy (CLSM) confirmed these insights by showing an up to 58% reduction in the treated biofilm thickness as compared to the control. Upon investigating the potential synergy of D-leucine and amikacin (defined as FICI index ≤0.5, with growth suppressive at and below OD600 of 0.1 for PA01 and 0.6 for PA14), the effective antibiotic concentrations lowered by 2–4 fold when compared to their individual MICs.
Conclusions: These results can be explained by D-leucine potentially substituting the position of L-leucine in leucine aminopeptidase, an enzyme that is essential for biofilm formation, and as a result slowing or inhibiting biofilm development.3 Additionally, mutations in the dtd gene (deaminoacyl-tRNA deacylase) in P. aeruginosa PAO1, which prevents incorporation of D-amino acids into proteins, could allow D-amino acids to be mistakenly incorporated in place of L-amino acids, further contributing to its antibiofilm activity.4 Overall, these findings highlight D-leucine as a promising antibiotic adjuvant to new treatment regimens against biofilm associated AMR.
Objectives: In this study, D-leucine has been evaluated for its anti-biofilm activity against monomicrobial and polymicrobial biofilms of Pseudomonas aeruginosa. The synergistic interactions between D-leucine and amikacin against monomicrobial microbes were comprehended.
Methods: The potential of this amino acid was assessed using MIC assay, chequerboard assay, crystal violet staining and confocal fluorescence live/dead assay imaging techniques.
Results: D-leucine demonstrated significant biofilm inhibition by up to 63.3% reduction in density as compared to the untreated control biofilm at a concentration of 40 mM. Confocal fluorescence laser scanning microscopy (CLSM) confirmed these insights by showing an up to 58% reduction in the treated biofilm thickness as compared to the control. Upon investigating the potential synergy of D-leucine and amikacin (defined as FICI index ≤0.5, with growth suppressive at and below OD600 of 0.1 for PA01 and 0.6 for PA14), the effective antibiotic concentrations lowered by 2–4 fold when compared to their individual MICs.
Conclusions: These results can be explained by D-leucine potentially substituting the position of L-leucine in leucine aminopeptidase, an enzyme that is essential for biofilm formation, and as a result slowing or inhibiting biofilm development.3 Additionally, mutations in the dtd gene (deaminoacyl-tRNA deacylase) in P. aeruginosa PAO1, which prevents incorporation of D-amino acids into proteins, could allow D-amino acids to be mistakenly incorporated in place of L-amino acids, further contributing to its antibiofilm activity.4 Overall, these findings highlight D-leucine as a promising antibiotic adjuvant to new treatment regimens against biofilm associated AMR.
| Original language | English |
|---|---|
| Article number | dlaf230.063 |
| Pages (from-to) | iv25 |
| Number of pages | 1 |
| Journal | JAC-Antimicrobial Resistance |
| Volume | 7 |
| Issue number | Supplement_4 |
| DOIs | |
| Publication status | Published - 4 Dec 2025 |
| Event | British Society for Antimicrobial Chemotherapy Winter Conference 2025: Infection - International Convention Centre Birmingham, Birmingham, United Kingdom Duration: 27 Oct 2025 → 28 Oct 2025 https://bsac.org.uk/infection2025/ |